SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNUM.L Regulatory News (NUM)

  • There is currently no data for NUM

Trading Update

3 Apr 2023 07:00

RNS Number : 0335V
Numis Corporation PLC
03 April 2023
 

Numis Corporation Plc

Trading Update

3 April 2023

 

Numis Corporation Plc (Numis), the independent investment banking group, today issues a trading update in respect of the six-month period ended 31 March 2023.

 

Key highlights:

 

· Our diversified business model continues to deliver a resilient performance through the market cycle with revenue for first half of FY23 expected to be in the region of £64m, approximately 14% below the comparative period, despite weaker overall investment banking markets.

· The outlook for M&A remains encouraging, with a record first half for advisory.

· Continued scarcity of UK ECM transactions across the market has resulted in lower investment banking revenues.

· Following a good start to the year, equities revenues will be lower than the comparative period, due to both institutional income and trading businesses experiencing a weaker end to the half year.

· Our balance sheet remains strong with both liquidity and capital positions enabling the capacity to deliver shareholder returns and continued investment in our strategy to deliver growth through the market cycle.

 

 

Summary review

 

Investment banking

 

In the first half we have continued to build on the successful diversification of our UK investment banking business, delivering another strong advisory performance. M&A revenues have benefited from continued momentum in securing financial adviser mandates from our corporate broking client base.

 

In line with the broader industry, capital markets revenues will be materially lower than the comparative period. Whilst our ECM market share in the UK has increased relative to FY22, overall market levels of issuance remain at historic lows. Engagement with our corporate clients remains strong and we are encouraged by the investor support achieved in recent capital raising transactions. Growth capital solutions, our private markets business, has experienced a pick up in deal activity and pipeline development, following reduced market activity levels in H2 FY22. We are well positioned to advise the most ambitious growth companies globally and remain excited by the potential for this business as activity levels recover.

 

Equities

 

We continued to build our European client base during the period, in line with the strategy to enhance our distribution capability beyond the UK and support our EU ECM marketing efforts. Investor sentiment toward the UK remains relatively weak with domestic focused institutional investors experiencing persistent fund outflows during the period. As a result, institutional income was lower than the comparative period and our trading profit was flat over the last two months of the half year as market conditions remained challenging.

 

Outlook

 

The outlook for our advisory business remains positive with a good pipeline of both buy-side and sell-side mandates, reflecting both continued activity in the UK mid-market and the strength of our corporate relationships. Our strong corporate broking franchise ensures we are well positioned to benefit from a recovery in capital markets volumes, however, we do not envisage a meaningful change in market conditions in the short term. As a consequence, we believe that it is unlikely that the IPO market will see any meaningful pick-up during the remainder of our financial year to 30 September 2023.

 

Our balance sheet remains strong with both liquidity and capital positions providing the group with capacity to deliver shareholder returns and invest in our strategy to deliver growth through the market cycle. During the first half we enhanced our product offerings across investment banking and equities, and we will continue to selectively assess growth opportunities as they emerge during this period of ongoing market uncertainty.

 

Contacts:

 

Numis:

Noreen Biddle-Shah, Head of Communications

020 7260 1441

FTI Consulting LLP:

Edward Bridges

07768 216607

Daisy Hall

07807 298568

Ambrose Fullalove

07970 982748

Grant Thornton UK LLP (Nominated Adviser):

Philip Secrett

020 7728 2578

Harrison Clarke

020 7184 4384

Ciara Donnelly

020 7728 2889

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

 

Notes for Editors

Numis (LON: NUM) is an independent, international investment bank that partners with the most ambitious companies and investors, offering strategic advice, unique insights and connectivity to the capital markets.

 

Already a leader in the UK market, Numis is the adviser of choice for listed companies, including one-fifth of the FTSE 350 index, with an average market capitalisation of £1bn, and has acted on the most UK IPOs over the past decade.

 

Since 2016, Numis has diversified its strategy to grow its UK M&A franchise, expand internationally and develop its private markets business, which combined now account for almost half of investment banking revenues.

 

Numis is listed on London's AIM and has offices in London, New York and Dublin.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUASBRORUOOAR
Date   Source Headline
20th Mar 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
16th Mar 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Mar 201811:06 amRNSTransaction in Own Shares and Total Voting Rights
12th Mar 20183:00 pmRNSDirectors' Dealing
9th Mar 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
6th Mar 20184:00 pmRNSDirector's Dealing
23rd Feb 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Feb 20182:13 pmRNSHolding(s) in Company
15th Feb 201812:45 pmRNSHolding(s) in Company
13th Feb 20181:41 pmRNSHolding(s) in Company
13th Feb 201811:28 amRNSHolding(s) in Company
6th Feb 20181:17 pmRNSResult of AGM
6th Feb 20187:00 amRNSTrading update
5th Feb 201811:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Jan 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Jan 201812:00 pmRNSDirectors' Dealing
16th Jan 20187:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Jan 201811:00 amRNSTransaction in Own Shares and Total Voting Rights
8th Jan 20187:00 amRNSBoard Change
5th Jan 20189:14 amRNSTransaction in Own Shares and Total Voting Rights
3rd Jan 20187:00 amRNSAnnual Report and Annual General Meeting Notice
13th Dec 20173:00 pmRNSTransfer of Shares from Treasury to EBT and TVR
6th Dec 20177:00 amRNSPreliminary Results for the year ended 30 Sep 2017
29th Nov 20174:28 pmRNSTransaction in Own Shares and Total Voting Rights
21st Nov 201711:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Nov 201711:32 amRNSTransaction in Own Shares and Total Voting Rights
18th Oct 20173:00 pmRNSTransaction in Own Shares and Total Voting Rights
17th Oct 20173:00 pmRNSTransaction in Own Shares and Total Voting Rights
6th Oct 20177:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Oct 20177:32 amRNSTrading Update
29th Sep 20177:00 amRNSPurchase of Shares in Close Period
21st Sep 20177:00 amRNSCancellation of Share Premium Account
20th Sep 201711:00 amRNSTransaction in Own Shares and Total Voting Rights
18th Sep 20173:00 pmRNSHolding(s) in Company
14th Sep 20177:00 amRNSDirector's Dealing
12th Sep 20173:00 pmRNSTransaction in Own Shares and Total Voting Rights
5th Sep 20174:32 pmRNSTransaction in Own Shares and Total Voting Rights
4th Sep 20174:34 pmRNSTransaction in Own Shares and Total Voting Rights
4th Sep 201711:09 amRNSHolding(s) in Company
1st Sep 20172:24 pmRNSHolding(s) in Company
1st Sep 20172:23 pmRNSDirector's Dealing
1st Sep 201712:26 pmRNSTransaction in Own Shares and Total Voting Rights
30th Aug 201711:00 amRNSResult of General Meeting
11th Aug 20171:00 pmRNSNotice of Meeting and Proposed Capital Reduction
9th Aug 20173:34 pmRNSTransaction in Own Shares and Total Voting Rights
7th Aug 20177:00 amRNSTransaction in Own Shares and Total Voting Rights
1st Aug 20177:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Jul 20177:01 amRNSBoard Changes
28th Jul 20177:00 amRNSTrading Update
13th Jul 201711:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.